Dr. Richard Isaacson was featured in The Wall Street Journal discussing the evolving approach to diagnosing Alzheimer’s disease and the importance of distinguishing between biological risk and a clinical diagnosis. The article examines the ongoing debate among experts as new biomarker and blood tests become more widely available.

Dr. Isaacson emphasized the need for careful interpretation of these emerging tools:

“You can’t diagnose 47 million Americans with Alzheimer’s disease. These Americans have biological markers of Alzheimer’s disease risk starting in their brain and detectable in their blood. It doesn’t mean all 47 million Americans have a stigmatizing diagnosis like Alzheimer’s.”

Read the full Wall Street Journal article to learn more about the evolving science of Alzheimer’s diagnosis and what new biomarker testing means for patients and clinicians.